ViroPharma Incorporated (NASDAQ: VPHM)

Sector: Medical

Current Price : $27.04

52 Week Low
$19.2452 Week High
$30.71

Press Releases
ViroPharma Proudly Supports HAE Day :-) 2013
ViroPharma To Participate In Two May Healthcare Investor Conferences
Biota Pharmaceuticals Announces Changes to Its Board of Directors
ViroPharma Announces First Quarter 2013 Financial Results
ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
News Alert: ViroPharma reinforces commitment to address medical needs and provide innovative treatment options for patients with adrenal insufficiency at ECE
AWMSG Recommends Cinryze?? (C1 Inhibitor [Human])for Routine Prevention, Treatment and Pre-Procedural Preventionof Hereditary Angioedema (HAE) Attacks in Adults and Adolescents in Wales
ViroPharma is Proud to be a Friend of Rare Disease Day 2013!
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On February 27, 2013
Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High
ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
Free Research Reports on RSYS, SNTS, VPHM and VRTX Issued by the Bedford Report
Sub-Group Analysis Of Data From Pediatric Patients With Hereditary Angioedema Published In The Journal Of Pediatrics
ViroPharma Provides 2013 Outlook
Should Recent Insider Selling on FFIV, RHT, ALXA and VPHM Matter to You?
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2b Dose Ranging Combination Study for Subcutaneous Administration of Cinryze? (C1 esterase inhibitor [human]) With Hyaluronidase (rHuPH20)
ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
ViroPharma To Participate In Two December Healthcare Investor Conferences
ViroPharma's Cinryze? (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema
ViroPharma To Participate In Two November Healthcare Investor Conferences
New Data On The Challenges Of Cost Effectiveness Modeling In Paediatric Use Marketing Authorisation (PUMA) HTA Submissions Presented 15TH Annual European Congress Of The International Society For Pharmacoeconomics And Outcomes Research (ISPOR)
Health Canada Approves New Drug Submission for Cinryze(tm) (C1 inhibitor [human])
ViroPharma To Release 2012 Third Quarter Financial Results On October 25, 2012
ViroPharma Presents New Cinryze? (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference
ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze? (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
ViroPharma Announces The First EU Market To Launch Plenadren? (Hydrocortisone, Modified-Release Tablet) For Treatment Of Adrenal Insufficiency, The First New Treatment Innovation For Over 50 Years
ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
Patients with Adrenal Insufficiency Report a Need for Improved Management of Their Condition
ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
The Shuman Law Firm Investigates ViroPharma, Inc.
ViroPharma Receives FDA Approval of Cinryze? (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
ViroPharma Provides Update on Phase 2 Clinical Evaluation of Subcutaneous Cinryze? (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
ViroPharma's Cinryze? (C1 esterase inhibitor [human]) Open Label Prophylaxis Study Showed Up To 2.6 Years Of Effectiveness In Majority Of Subjects With Hereditary Angioedema
ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
Law Office of Brodsky & Smith, LLC Announces Investigation of Viropharma Incorporated
INVESTOR ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Large Financial Interests of Important Deadline in Lawsuit Against ViroPharma Inc. - VPHM
Pomerantz Law Firm Reminds Shareholders of ViroPharma Incorporated of Upcoming Deadline -- VPHM
UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses on Their Investment in ViroPharma Incorporated of Class Action Lawsuit and the Deadline of July 17, 2012 to Seek a Lead Plaintiff Position
ViroPharma To Participate In The JMP Securities Healthcare Conference
Pomerantz Law Firm Reminds Shareholders of ViroPharma Incorporated of Upcoming Deadline - VPHM
ViroPharma's Buccolam? (Midazolam, Oromucosal Solution) Licensed in Ireland for Emergency Treatment of Seizures in Children and Adolescents
ViroPharma's Buccolam?? (Midazolam, Oromucosal Solution) now Available in Wales for Treatment of Prolonged Acute Convulsive Seizures
The Shuman Law Firm Announces the Filing of a Class Action Lawsuit Against ViroPharma, Inc.
Pomerantz Law Firm Reminds Shareholders of ViroPharma Incorporated of Upcoming Deadline -- VPHM
Today's Market Driven by Key Factors - Featured Research on Viropharma Inc and Campbell Soup Company
The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in ViroPharma Incorporated of Class Action Lawsuit and the Deadline of July 17, 2012 to Seek a Lead Plaintiff Position
ViroPharma Announces Initiation of Clinical Studies to Evaluate Maribavir for Treatment of Cytomegalovirus (CMV) Infection
Pomerantz Law Firm Reminds Shareholders of ViroPharma Incorporated of Upcoming Deadline -- VPHM
Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates ViroPharma, Inc. For Securities Fraud
Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
ViroPharma Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Announce Investigation Into ViroPharma Incorporated
The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in ViroPharma Incorporated of Class Action Lawsuit and the Deadline of July 17, 2012 to Seek a Lead Plaintiff Position
The Lin Law Firm Announces That a Securities Class Action Lawsuit Against ViroPharma Incorporated Has Been Filed
Izard Nobel LLP Announces Class Action Lawsuit Against ViroPharma Incorporated
Pomerantz Law Firm Has Filed a Class Action Against ViroPharma Incorporated -- VPHM
Brower Piven Encourages Investors Who Have Losses in Excess of $500,000 from Investment in ViroPharma Incorporated to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the July 17, 2012 Lead Plaintiff Deadline - VPHM
ViroPharma To Participate In Two June Healthcare Investor Conferences
Rosen Law Firm Announces Securities Class Action Against ViroPharma Incorporated Seeking to Recover Investor Losses -- VPHM
Investor Alert: Former Louisiana Attorney General and Kahn Swick & Foti, LLC, Remind Investors with Large Financial Interests of Lead Plaintiff Deadline in Class Action Lawsuit Against ViroPharma Inc.
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ViroPharma Incorporated
Plenadren? (Hydrocortisone, Modified Release Tablet) Data Presented at 2012 Joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology (ICE/ECE)
ViroPharma Announces Upcoming Data Presentation Of Plenadren? (Hydrocortisone, Modified Release Tablet) At 2012 Joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology (ICE/ECE)
Holzer Holzer & Fistel, LLC Announces Investigation into ViroPharma Incorporated
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Securities Laws Violations by ViroPharma Inc.
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ViroPharma, Inc.
Prasco Expands Authorized Generic Product Line with Vancocin? HCl Capsules
Investor Alert: Former Attorney General of Louisiana and Kahn Swick & Foti, LLC Investigate ViroPharma Inc., Following Disclosure of Federal Trade Commission Investigation
ViroPharma Provides Update on Status of Citizen Petition Regarding Bioequivalence and Exclusivity for Vancocin? (vancomycin hydrochloride, USP) Capsules
ViroPharma Launches Hereditary Angioedema Facebook App to Encourage Education and Diagnosis of Hereditary Angioedema Through Discussion of Family History
ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze? (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
Cinryze?? (C1 Inhibitor [Human]) Now Available in the UK for Routine Prevention of Hereditary Angioedema (HAE) Attacks
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
ViroPharma to Release 2011 Fourth Quarter and Full Year Financial Results on February 28, 2012
A Forward Look, The Year Ahead - Featured Research on ViroPharma Incorporated and Salix Pharmaceuticals, Ltd.
ViroPharma to Participate in Two Upcoming Healthcare Investor Conferences
Scottish Medicines Consortium Accepts for use Viropharma's Buccolam?? (Midazolam, Oromucosal Solution) for Treatment of Prolonged Acute Convulsive Seizures
ViroPharma Provides Update on Industrial Scale Supplement for Cinryze? (C1 Esterase Inhibitor [Human])
ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma
ViroPharma Announces Approval of Modernized Labeling for Vancocin? (vancomycin hydrochloride, USP) Capsules
ViroPharma's Buccolam?? (Midazolam, Oromucosal Solution) now Available in the United Kingdom as Licenced Product for Emergency Treatment of Seizures in Children and Adolescents
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze? (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
ViroPharma to Participate in Two December Healthcare Investor Conferences
ViroPharma Completes Acquisition of DuoCort Pharma AB
DuoCort Pharma's Orphan Drug Plenadren? Granted European Marketing Authorization for Adrenal Insufficiency
ViroPharma to Participate in Two November Healthcare Investor Conferences
ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia
ViroPharma Expands Its Innovative "HAE and Me" Online Community With Education and Support to Meet Unique Needs of Hereditary Angioedema Caregivers
ViroPharma Announces Additional Securities Repurchase Program
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze? (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
ViroPharma's Buccolam? (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
ViroPharma Announces Positive CHMP Opinion for Buccolam? (Midazolam, Oromucosal Solution) in the European Union
ViroPharma's Cinryze? (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Nine Abstracts Relating to Cinryze? (C1 Esterase Inhibitor [human]) Data Presented at 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI)
Nine Abstracts Relating to Cinryze(R) (C1 Esterase Inhibitor [human]) Data Presented at 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI)
ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference

Two Week FREE Trial

iStock Rating

ViroPharma Incorporated (NASDAQ: VPHM)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios